Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Fusen Pharmaceutical Company Limited
福森藥業有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1652)

VOLUNTARY ANNOUNCEMENT
NOTIFICATION OF APPROVAL OF CONSISTENCY EVALUATION OF "NICARDIPINE HYDROCHLORIDE INJECTION"

The board of directors (the "**Board**") of Fusen Pharmaceutical Company Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that the Company has received the Notification of Approval issued by the National Medical Products Administration of the PRC, with respect to the application for consistency evaluation of "Nicardipine Hydrochloride Injection", developed by the Group's wholly-owned subsidiary, Henan Fusen Pharmaceutical Company Limited* (河南福森藥業有限公司), for the emergency management of perioperative hypertension and hypertensive emergencies.

According to data from Menet, the sales volume of Nicardipine Hydrochloride Injection in Chinese public healthcare institutions exceeded RMB600 million in 2024. In recent years, the sales volume across the six major markets in China's three key terminals has expanded rapidly, maintaining double-digit growth from 2022 to 2024 with year-on-year increases of 35.71%, 16.09%, and 14.14%, respectively.

Nicardipine Hydrochloride is a new-generation dihydropyridine calcium channel blocker that selectively dilates arteries, enabling rapid and stable control of hypertensive emergencies. Nicardipine Hydrochloride Injection is recommended as a first-line treatment drug in certain hypertensive management scenarios, as stated in the 2020 Global Hypertension Practice Guidelines issued by the International Society of Hypertension. It is also recommended as a first-line intravenous antihypertensive drug for a broad range of conditions according to the "Guidelines for Diagnosis and Treatment of Hypertensive Emergencies in the PRC (中國高血壓急症診療規範)", being recommended by multiple guidelines both domestically and internationally.

Nicardipine Hydrochloride Injection offers several advantages, including rapid onset, stable blood pressure reduction, more comprehensive protection to target organs, non-toxic metabolites, safer application and stronger vascular selectivity, no impact on cardiac rhythm, improved myocardial safety, and balanced infusion for blood pressure control. The 5ml:5mg specification of Nicardipine Hydrochloride Injection developed by the Group has been sold in the domestic market in China for several years and enjoys a high level of market recognition. The specifications in this approval also include 2ml:2mg and 10ml:10mg. Fusen Pharmaceutical is one of the companies in China with the most comprehensive range of specifications for this product, meeting different treatment needs of patients. The quality and efficacy of Fusen Pharmaceutical's Nicardipine Hydrochloride Injection align with the reference formulation, making it a viable alternative to the original drug in clinical use. Nicardipine Hydrochloride Injection has demonstrated a promising prospect in the emergency management of perioperative hypertension and hypertensive emergencies.

By order of the Board
Fusen Pharmaceutical Company Limited
Mr. Cao Zhiming
Chairman and Executive Director

* *For identification purpose only*

12 December 2025

As at the date of this announcement, the Board of the Company comprises Mr. Cao Zhiming (Chairman), Mr. Hou Taisheng, Mr. Chi Yongsheng and Ms. Meng Qingfen as executive Directors and Mr. Lee Kwok Tung Louis, Dr. To Kit Wa and Mr. Yu Ho Ming as independent non-executive Directors.